<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:19:21Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/33591" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/33591</identifier><datestamp>2026-09-24T19:50:58Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Tang, damu</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Dong,Ying</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2026-09-23T17:45:04Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2026</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/11375/33591</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/25362</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Renal cell carcinoma (RCC) is the predominant cause of kidney cancer death, owing
to the disease’s aggressiveness-associated poor prognosis as well as challenges in early
diagnosis and in predicting RCC evolution path, particularly in response to therapy.
Currently, RCC cases are diagnosed incidentally through imaging; the disease prognosis
is evaluated based on tumors’ histological features; and immune checkpoint inhibitor
(ICI) is promising in treating patients with advanced RCC by taking advantage of
enriched infiltration of CD8+ T cells without reliable criteria (biomarkers) for optimizing
ICI therapy.
My research focuses on advancing the current understanding of RCC particularly
factors relevant to RCC’s immune escape and identifying novel and effective biomarkers
to improve patient management. Specifically, we investigated novel factors: Contactin 1
(CNTN1) and CYTH4 for their contributions to RCC progression, and multigene panels,
Sig27 and SigRZ, as novel predictive biomarkers of RCC. Notably, CNTN1, CYTH4,
and Sig27 display intrinsic connections with the immunosuppressive microenvironment
of RCC.
Contactin 1 (CNTN1) is a cell adhesion protein and has been reported to be associated
with tumor invasion, metastasis, and poor prognosis across multiple cancer types. In this
study, we demonstrate that CNTN1 expression is strongly associated with tumor
aggressiveness and adverse clinical outcomes in RCC. Tumors with high expression of
CNTN1 show upregulation of genes and pathways involved in cell proliferation,
migration, and extracellular matrix remodeling, consistent with a highly invasive tumor
state, and elevated CNTN1 expression correlates with enrichment of immunosuppressive

signaling pathways and immune cell populations. In vitro, CNTN1 promotes tumor cell
migration and invasion. In vivo, CNTN1-overexpressing Renca (Renca-CNTN1)
allograft exhibits a biphasic growth, an early growth suppression followed by later
acceleration compared to Renca-EV (empty vector) allografts. Surgical resection of early
tumors (100 mm3) showed CNTN1 tumors recur at lower rates (3/10=30%) than EV
allografts (10/10=100%), indicating that Renca-CNTN1 allografts initiate anti-tumor
immunity which suppresses early tumor growth and their subsequent recurrence
following surgical resection. Tumor cells isolated from recurrent Renca-CNTN1 tumors
produced aggressive allografts in BALB/c mice compared to tumor cells isolated from
Renca-EV recurrent tumors. Renca-CNTN1 tumors that escape this immunosurveillance
window develop interferon-dominated transcriptional programs with co-expression of the
exhaustion markers TOX, PD-1, and LAG-3, alongside CD8+ T cell infiltration with
impaired cytolytic function. CNTN1 thus drives a stage-dependent immune evasion
program in RCC, coupled with enhancing proliferation and the relevant pathways.
CYTH4 (Cytohesin 4), a regulator of ARF-mediated signaling and cytoskeletal
dynamics, was selectively enriched in immune cell subsets exhibiting altered migratory
and suppressive properties. Dysregulation of CYTH4 was associated with tumor
initiation and progression, highlighting its contribution to immune cell trafficking and
functional reprogramming within the tumor microenvironment (TME). CYTH4
(Cytohesin-4) was identified as a novel oncogenic factor in ccRCC, with expression
upregulated in tumor, lymph node metastasis, and the aggressive ccB subtype. In vitro,
overexpression of CYTH4 in 786-O cells enhanced colony formation and produced more
aggressive xenografts in NOD/SCID mice. Mechanistically, CYTH4 physically
interacted with PPP1R9B to induce pRb hyperphosphorylation. RNA-seq of CYTH4
xenografts showed enrichment of MYC Targets and E2F Targets alongside upregulation
of the Sig27 metagene, with three Sig27 component genes confirmed as CYTH4-
associated differentially expressed genes (DEGs). A derived 13-gene panel
SigCYTH4NW robustly stratified poor overall survival across four ccRCC cohorts and
21 cancer types with stable hazard ratios strongly correlated with an immune checkpoint
panel (SigIC), and showed predominant expression in tumor-associated macrophages
(TAMs), exhausted CD8+ T cells, and Tregs in single-cell datasets.
We validated a prostate cancer-derived and IQGAP1 associated novel 27-gene
prognostic signature (Sig27) that robustly predicts poor prognosis in RCC. Sig27
presented a strong association with immunosuppressive features of the TME, including
myeloid infiltration and immune inhibitory signaling. To further explore the clinical
relevance of this, we constructed SigRZ, a 2-gene signature for predicting overall
survival and disease progression in advanced RCC patients treated with the PD-1
inhibitor nivolumab. SigRZ effectively stratified patients by clinical outcome,
underscoring the relevance of immune-associated transcriptional programs in
determining immunotherapy response.
Collectively, we identified two factors as promoters of tumor aggressiveness and tumor
microenvironment changes. The development or validation of Sig27 and SigRZ
demonstrates the translational potential of integrating tumor-intrinsic and immuneassociated
molecular programs into clinically actionable biomarkers. Taken together, the
findings advance our understanding of immune-driven tumor progression and provide a
conceptual framework for biomarker development for RCC progression.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="title">Identification and Characterization of Novel Oncogenic Factors and Predictive Biomarkers of Clear Cell Renal Cell Carcinoma</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>